Shire PLC (ADR) (SHPG) was Initiated by Stifel to “Buy” and the brokerage firm has set the Price Target at $230. Stifel advised their investors in a research report released on May 26, 2016.
Many Wall Street Analysts have commented on Shire PLC (ADR). Shire PLC (ADR) was Initiated by Liberum to “Buy” on May 6, 2016.
On the company’s financial health, Shire PLC (ADR) reported $2.12 EPS for the quarter, beating the analyst consensus estimate by $ 1.11 according to the earnings call on Apr 29, 2016. Analyst had a consensus of $1.01. The company had revenue of $1709.00 million for the quarter, compared to analysts expectations of $1699.64 million. The company’s revenue was up 14.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.08 EPS.
Shire PLC (ADR) opened for trading at $191.41 and hit $192.02 on the upside on Wednesday, eventually ending the session at $191.78, with a gain of 2.11% or 3.96 points. The heightened volatility saw the trading volume jump to 39,13,773 shares. Company has a market cap of $37,854 M.
Shire plc is a biopharmaceutical company. The Company along with its subsidiaries is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience Gastrointestinal (GI) Rare Diseases and Other therapeutic areas. The Companys products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate) ADDERALL XR (mixed salts of a single-entity amphetamine) INTUNIV (extended release guanfacine) EQUASYM (methylphenidate hydrochloride) modified release (XL) BUCCOLAM LIALDA (mesalamine)/ MEZAVANT(mesalazine) PENTASA (mesalamine) RESOLOR (prucalopride) REPLAGAL (agalsidase alfa) VPRIV (velaglucerase alfa) FIRAZYR (icatibant) CINRYZE C1 esterase inhibitor (human) FOSRENOL (lanthanum carbonate) XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).